Literature DB >> 115586

Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.

M M Ames, G Powis, J S Kovach, R T Eagan.   

Abstract

The disposition and metabolism of pentamethylmelamine (PMM) and hexamethylmelamine (HMM) were studied in the rabbit, and the disposition of PMM was studied in humans. Parent compound and metabolites were identified by thin-layer chromatography, gas chromatography, and gas chromatography/mass spectrometry analyses. Plasma elimination in both species following i.v. administration of each drug was best described by a two-compartment open model. Both compounds were extensively demethylated with less than 1% of the total dose administered recovered in the urine over 24 hr. The areas under the plasma time-concentration curves of PMM and HMM following p.o. administration to rabbits were 5 and 25% of the areas following i.v. administration. Gastrointestinal absorption was rapid and efficient with 75 to 89% of drug equivalents recoverable in the urine after p.o. administration of [ring-14C]PMM or [ring-14C]HMM to rabbits. Reduced bioavailability of PMM and HMM p.o. appears to be a consequence of rapid metabolism presumably in the liver.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 115586

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

Authors:  C J Rutty; I R Judson; G Abel; P M Goddard; D R Newell; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

Authors:  C J Rutty; D R Newell; J R Muindi; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 3.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 4.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Dose-dependent pharmacokinetics of PMM in the rat.

Authors:  T Colombo; L Torti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.

Authors:  K J Miller; R M McGovern; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 8.  Hexamethylmelamine and hexamethylmelamine hydrochloride.

Authors:  H P van de Vaart-van Zutphen; C F Smulders; J Renema; A Hulshoff
Journal:  Pharm Weekbl Sci       Date:  1982-04-23

9.  Increased nephrotoxicity after combined administration of melamine and cyanuric Acid in rats.

Authors:  Dongsun Park; Tae Kyun Kim; Young Jin Choi; Sun Hee Lee; Dae-Kwon Bae; Goeun Yang; Yun-Hui Yang; Seong Soo Joo; Ehn-Kyoung Choi; Byeongwoo Ahn; Jong-Choon Kim; Kil-Soo Kim; Yun-Bae Kim
Journal:  Lab Anim Res       Date:  2011-03-26

10.  Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.

Authors:  J R Muindi; D R Newell; I E Smith; K R Harrap
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.